Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Valspodar. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 known ✓ | P08183 | 14/20 | 1.00 |
| ▸ | ABCC1 | P33527 | 2/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 2/20 | 1.00 |
| ▸ | PPIA | P62937 | 4/20 | 0.69 |
| ▸ | PPP3CA | Q08209 | 3/20 | 0.69 |
| ▸ | FKBP1B | P68106 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.69 |
| ▸ | GMNN | O75496 | 1/20 | 0.69 |
| ▸ | USP2 | O75604 | 1/20 | 0.69 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | RARB | P10826 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valspodar SCHEMBL19499881 | 1.00 | ABCB1 (1.00) | ABCB1ABCC1ABCC2PPIAPPP3CA | |
| Valspodar SCHEMBL19639131 | 1.00 | ABCB1 (1.00) | ABCB1ABCC1ABCC2PPIAPPP3CA | |
| Valspodar SCHEMBL19639132 | 1.00 | ABCB1 (1.00) | ABCB1ABCC1ABCC2PPIAPPP3CA | |
| Valspodar SCHEMBL18671913 | 1.00 | ABCB1 (1.00) | ABCB1ABCC1ABCC2PPIAPPP3CA | |
| Valspodar SCHEMBL21118455 | 1.00 | ABCB1 (1.00) | ABCB1ABCC1ABCC2PPIAPPP3CA | |
| Valspodar SCHEMBL24062361 | 1.00 | ABCB1 (1.00) | ABCB1ABCC1ABCC2PPIAPPP3CA | |
| SCHEMBL29307747 | 0.97 | ABCB1 (0.95) | ABCB1ABCC1ABCC2PPIAPPP3CA | |
| SCHEMBL22882366 | 0.96 | ABCB1 (0.92) | ABCB1ABCC1ABCC2PPIAPPP3CA | |
| SCHEMBL25087720 | 0.96 | ABCB1 (0.92) | ABCB1ABCC1ABCC2PPIAPPP3CA | |
| SCHEMBL24406589 | 0.95 | ABCB1 (0.91) | ABCB1ABCC1ABCC2PPIAPPP3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6224 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12364682-B2 | Use of tegaserod in preparation of anti-tumor drug | QINGDAO HAIJI BIOMEDICINE CO., LTD. (CN) | 2025-07-22 | — | — | US | claimed |
| US-20250152591-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS | KURA ONCOLOGY INC (US) | 2025-05-15 | — | — | US | claimed |
| US-20250059301-A1 | Fusion Protein Construct | NORTHWESTERN UNIVERSITY | 2025-02-20 | — | — | US | claimed |
| WO-2025027194-A1 | A METHOD OF PREPARING AN AQUEOUS DISPERSION OF NANOPARTICLES | IQ MEDICAL GMBH (DE) | 2025-02-06 | — | — | WO | claimed |
| WO-2025027196-A1 | A METHOD OF PRODUCING NANOPARTICLES OF A DEFINED SIZE | IQ MEDICAL GMBH (DE) | 2025-02-06 | — | — | WO | claimed |
| EP-4501320-A1 | A METHOD OF PREPARING AN AQUEOUS DISPERSION OF NANOPARTICLES | IQ medical GmbH (DE) | 2025-02-05 | — | — | EP | claimed |
| US-20240415940-A1 | HYALURONIDASE POLYPEPTIDE FOR USE IN THE TREATMENT OR PROPHYLAXIS OF A NEURODEGENERATIVE DISEASE | PHARMACT HOLDING AG (CH) | 2024-12-19 | — | — | US | claimed |
| EP-4472637-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS | Kura Oncology, Inc. (US) | 2024-12-11 | — | — | EP | claimed |
| EP-4419125-A1 | HYALURONIDASE POLYPEPTIDE FOR USE IN THE TREATMENT OR PROPHYLAXIS OF A NEURODEGENERATIVE DISEASE | Pharmact Holding AG (CH) | 2024-08-28 | — | — | EP | claimed |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | EDISON ONCOLOGY (US) | 2024-05-16 | — | — | US | claimed |
| EP-1260233-A1 | P-GLYCOPROTEIN MODIFIER-CONTAINING MEDICINAL COMPOSITIONS TO BE DELIVERED TO THE LARGE INTESTINE | HISAMITSU PHARMACEUTICAL CO. INC. (JP) | 2002-11-27 | — | — | EP | claimed |
| US-20020156124-A1 | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability | PHARMACIA & UPJOHN COMPANY | 2002-10-24 | — | — | US | claimed |
| US-20020142950-A1 | Methods for enhancing the bioavailability of a drug | PRAECIS PHARMACEUTICALS, INC. | 2002-10-03 | — | — | US | claimed |
| WO-2002064132-A2 | CHEMOTHERAPEUTIC MICROEMULSION COMPOSITIONS OF PACLITAXEL WITH IMPROVED ORAL BIOAVAILABILITY | PHARMACIA & UPJOHN COMPANY (US) | 2002-08-22 | — | — | WO | claimed |
| EP-1232260-A2 | POLYMORPHISMS IN THE HUMAN MDR-1 GENE AND APPLICATIONS THEREOF | EPIDAUROS AG Biotechnologie Aktiengesellschaft (DE) | 2002-08-21 | — | — | EP | claimed |
| WO-2002056692-A1 | METHODS FOR MODULATING TUMOR GROWTH AND METASTASIS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-07-25 | — | — | WO | claimed |
| US-20020016293-A1 | Flavopiridol drug combinations and methods with reduced side effects | NIH - DEITR | 2002-02-07 | — | — | US | claimed |
| WO-2001080896-A2 | FLAVOPIRIDOL DRUG COMBINATIONS AND METHODS WITH REDUCED SIDE EFFECTS | ARCH DEVELOPMENT CORPORATION (US) | 2001-11-01 | — | — | WO | claimed |
| WO-2001058470-A2 | METHODS FOR ENHANCING THE BIOAVAILABILITY OF A DRUG | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2001-08-16 | — | — | WO | claimed |
| WO-2001009183-A2 | POLYMORPHISMS IN THE HUMAN MDR-1 GENE AND APPLICATIONS THEREOF | EPIDAUROS (DE) | 2001-02-08 | — | — | WO | claimed |